Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
07:30am, Wednesday, 06'th Aug 2025
WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
07:00am, Wednesday, 06'th Aug 2025
– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong phys
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
07:00am, Wednesday, 30'th Jul 2025
WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
07:00am, Tuesday, 29'th Jul 2025
– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal communit
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Wednesday, 16'th Jul 2025
WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Monday, 16'th Jun 2025
WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
11:03am, Thursday, 12'th Jun 2025
EyePoint Pharmaceuticals, Inc.'s Duravyu shows promising Phase 2 results in DME, supporting a slightly risky 'Buy' call ahead of pivotal Phase 3 readouts in 2026. Duravyu's potential for less frequent
Breakout Momentum Plays You May Not Know About
11:54am, Friday, 06'th Jun 2025
High volatility has plagued markets throughout much of 2025. While many consider this a bad thing, particularly when trends point downward, it can also create opportunities for momentum investors to c
EyePoint Announces Participation at Upcoming Investor Conferences
04:01pm, Wednesday, 28'th May 2025
WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration
07:00am, Tuesday, 27'th May 2025
– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest –
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Friday, 16'th May 2025
WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patien
EyePoint Announces Participation at Upcoming Investor Conferences
07:00am, Tuesday, 13'th May 2025
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript
02:49pm, Wednesday, 07'th May 2025
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants George Elston - Executive Vice President & Chief Financial Officer Jay Duker
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say
10:36am, Wednesday, 07'th May 2025
The headline numbers for EyePoint Pharmaceuticals (EYPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wal
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
09:25am, Wednesday, 07'th May 2025
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago.
